Key facts
- This page summarizes David G. Kelly's Form 4 filing for Iterum Therapeutics plc (ITRM).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 17 Jun 2022, 17:01.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Award
Additional SEC filing notes
Footnote F1
Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated 2018 Equity Incentive Plan, as amended, the shares subject to this option shall vest in full on June 15, 2023